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Aim: Excipients are used to overcome the chemical, physical and microbiological 
challenges posed by developing formulated medicines. Both methyl and propyl 
paraben are commonly used in pediatric liquid formulations. There is no data on 
systemic exposure to parabens in neonates. The European Study of Neonatal Exposure 
to Excipients project has investigated this. Results & methodology: DBS sampling was 
used to collect opportunistic blood samples. Parabens were extracted from the DBS 
and analyzed using a validated LC–MS/MS assay. Discussion & conclusion: The above 
assay was applied to analyze neonatal DBS samples. The blood concentrations of 
parabens in neonates confirm systemic exposure to parabens following administration 
of routine medicines.
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Pediatric liquid formulations contain the 
active pharmaceutical ingredient and excipi-
ents. To overcome the physical, chemical 
and microbiological challenges in these 
formulations, excipients are normally used. 
The commonly used excipients in pediatric 
formulations are methyl (MPB) and pro-
pyl paraben (PPB), which are the methyl 
and propyl esters of p-hydroxybenzoic acid, 
respectively Figure 1. Acceptable daily intake 
of MPB has been established for adults at 10 
mg/kg bw/day [1]. No acceptable daily intake 
has been assigned to PPB. Until recently, 
there has been no data on systemic expo-
sure to parabens in human neonates. There 
are long standing concerns about parabens 
relating to the possibility of oestrogenic 
effects and cell physiology, which could 
cause adverse long-term outcomes. Previous 
work assessments of exposure to excipients 
in neonates have been based on estimates 
of intake [2]. In order to move from theo-
retical extrapolations of exposure based on 
estimates of intake, the European Study of 
Neonatal Exposure to Excipients (ESNEE) 
project conducted studies within a clinical 
environment to define systemic exposure of 
MPB and PPB in neonates. An observational 
study of systemic concentrations of parabens 
in human neonates could provide a good 
indication as to the range of exposures in 
neonates during their routine clinical care.
To study the PK of drugs, the biological 
matrix of choice is blood plasma. Quanti-
fication of drugs or excipients in the blood 
samples taken from neonates is very chal-
lenging. The total circulating volume of 
blood [3] in preterm and term neonates is 
very low (80–90 ml/kg or ∼45–360 ml). 
The DBS sampling approach was used in 
this study for clinical and ethical reasons, as 
multiple plasma sampling (which is a prereq-
uisite for PK studies) is not always possible 
in this age range. Emmons and Rowland 
have discussed the application of DBS to 
study PK [4].
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Figure 1. Chemical structures of parabens used in the 
study.
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Parabens have been quantified in a range of matri-
ces using high performance liquid chromatography 
coupled with the following detectors; UV [5–8], pho-
todiode array [9] and MS/MS [10–22]. GC has also 
been used with free induction decay [23], TOF [24] and 
MS [25] as has thin layer chromatography [10]. The bio-
logical matrices used included urine [5,12,14,16,18–19,22], 
serum [14,17], seminal plasma [14], breast tissue [10], 
placental tissue [15], saliva [6], breast milk [13,21] and 
rat plasma [20]. Parabens have also been determined 
in water [24,25], personal care products [6,8,11,23,26] and 
pharmaceutical preparations [7,9].
Several sample preparation methodologies have been 
reported to facilitate the extraction of parabens from 
the above tissues. These approaches include SPE [12–
13,19,22,24], LLE [8,14,16,18,20–21,23], dispersive LLE [17], 
solvent extraction [5–6,10,15,26], stir-bar sorptive extrac-
tion [25], super critical extraction [11] and simple protein 
precipitation [20].
The first person to use the DBS technology in 
infants to screen in-born errors of metabolism was R 
Guthrie [27]. In comparison to the venous sampling, 
the DBS technique has proven to be minimally inva-
sive. This sampling technique can be used at home 
or in the clinical settings, as it requires less training. 
Storing and shipping these samples in dried form is 
very safe [28,29]. Our group has previously reported 
similar applications involving DBS [30–34] to develop 
bioanalytical methods.
Herein, we report the development and validation of 
an assay to support the clinical measurement of MPB 
and PPB from DBS by LC–MS/MS. This is the first 
report describing the quantification of parabens in the 
DBS samples.
Materials & methods
Chemicals & reagents
Analytical grade reagents and chemicals were used 
for all the extractions and assays. Methyl, propyl 
and benzyl paraben (BPB) (Figure 1) were purchased 
from Sigma (Poole, UK). BPB was used as an inter-
nal standard (IS). HPLC grade solvents and water, 
buffers, Oasis® HLB cartridges (1 cc/30 mg) were 
all purchased as mentioned in our previous publica-
tion [32]. The School of Pharmacy Ethical Commit-
tee (013PMY2009) approved the collection of blank 
blood from healthy human volunteers
Ahlstorm 226 (Guthrie cards) together with stor-
age pouches were purchased from 3M Security Sys-
tems Division (Oldham, England). A 8 mm single 
hole punch (2700–62) used to cut out the DBS disks 
from the cards was purchased from Darice, Strongs-
ville, Ohio, USA. Zip-loc bags, silica gel pouches and 
freezer storage lunch boxes were procured from the 
Amazon website. Manual SPE manifold (Waters Dub-
lin, Ireland) was used for SPE. For solvent evapora-
tion, Zymark Turbo Vap® LV Evaporator workstation 
(Zymark, Runcorn, UK) was used. Eppendorf tubes 
2 ml (Sarstedt, Numbrecht, Germany) were used for 
the initial extraction of the DBS samples. Stuart rota-
tor SB2 and vortex mixer SA8 (Bibby Scientific, Staf-
fordshire, UK) were used to mix the spiked blood and 
vortex samples, respectively.
Chromatography
Waters Alliance HT system 2795 (Waters, Dublin) 
was the LC system used for separation. A XBridgeTM 
C18 column (3.5 μm, 4.6×100 mm) was used along 
with XBridge (3.5 μm, 4.6 × 20 mm) guard column, 
which had a matching chemistry. Both the columns 
were maintained at 25°C during the chromatographic 
separation. Mobile phase consisted of methanol/5 mM 
ammonium acetate (99:1 v/v) with a flow rate of 
0.3 ml/min.
Mass spectrometry
The above LC system was hyphenated to Waters 
Micromass Quattro PremierTM tandem quadrupole 
(Waters, Manchester, UK).
The MS conditions for the electrospray negative ion 
mode (ESI-) were optimized at the following condi-
tions: Cone gas (nitrogen) 75 l/h, desolvation gas 
(nitrogen) 800 l/h, desolvation temperature 400°C, 
source temperature 145°C and capillary voltage 2.60 V. 
Argon gas was used as the collision gas.
The following multiple reaction monitoring 
transitions were setup for quantitation of each ion:
•	 MPB: For molecular ion, quadrupole 1 was set at 
m/z 150.90 and for product ion quadrupole 2 at 
m/z 91.80. The cone voltage and collision energy 
for the product ion, the detector was set at 20 V 
and 25 eV, respectively.
•	 PPB: For molecular ion, quadrupole 1 was set at 
m/z 178.96 and for product ion quadrupole 2 at 
m/z 91.80. The cone voltage and collision energy 
for the product ion, the detector was set at 23 V and 
26 eV, respectively.
O OR
OH
R = -CH3 Methyl paraben
R = -CH2-CH2-CH3 Propyl paraben
R = -C6H5 Benzyl paraben
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•	 BPB (IS): For molecular ion, quadrupole 1 was set 
at m/z 227.00 and for product ion quadrupole 2 at 
m/z 91.80. The cone voltage and collision energy 
for the product ion, the detector was set at 25 V 
and 24 eV, respectively.
For each ion the dwell time was set at 0.05 s.
Software
MassLynxTM 4.1 Software was used to control the LC 
system and the mass spectrometer and the data were 
processed using QuanLynx Application Manager.
Sample preparation
Preparation of spiked standards & working 
solutions
The stock (1 mg/ml) and working standards for MPB, 
PPB and BPB were prepared in methanol. The work-
ing calibration standards of MPB and PPB (prepared 
and mixed in the same pot) were prepared at the con-
centrations 50, 25, 20, 5, 4, 2.5 and 1 μg/ml. Simi-
larly MPB and PPB (prepared and mixed in the same 
pot) working quality control (QC) standards were 
prepared separately at concentrations 40, 10, 2 and 
1 μg/ml. A 5 ng/ml working standard of IS was pre-
pared. All the above solutions were stored at 4°C and 
were brought to (20°C) room temperature, before use.
Spiking of whole blank blood for the preparation 
of calibration & QC samples
Calibration standards: to 980 μl of whole blood, 20 μl 
of the appropriate MPB + PPB working standard solu-
tion containing 50, 25, 20, 5, 4, 2.5 and 1 μg/ml was 
spiked to give final concentrations of 1000, 500, 400, 
100, 80, 50 and 20 ng/ml.
Similarly, the QC samples at concentration 20 ng/ml 
(LOQ), 40 ng/ml (low QC), 200 ng/ml (middle QC) 
and 800 ng/ml (high QC) were prepared by spiking 
20 μl of MPB working solutions 1, 2, 10 and 40 μg/ml 
to 980 μl of whole blood, respectively.
Blood spotting
Spiked blood was mixed very slowly by rotating for 
45 min at room temperature before spotting. This 
was done for the equilibration of the parabens in the 
blood. The blood spots were prepared by accurately 
transferring 15 μl of the spiked blood, using a cali-
brated pipette from both (calibration and QC stan-
dards) onto Ahlstorm 226 cards. The samples were 
dried for 3 h at room temperature in the dark (cup-
board) and then placed in zip lock bags along with 
silica gel pouches. The cards were then stored in poly-
propylene freezer storage sealed containers at -20°C 
until analysis.
Extraction procedure for DBS samples
The DBS samples were brought to room temperature 
before analysis. An 8 mm disk was punched from the 
card, wherein the complete blood spot was captured. 
This was then transferred to 2 ml eppendorf tubes and 
extracted by addition of 1 ml of methanolic BPB (IS) 
solution (5 ng/ml), followed by vortex mixing for 30 
min. The extracts were then evaporated to dryness 
under nitrogen on the Zymark Turbovap at 37°C and 
reconstituted with 1 ml of milli-Q water, followed by 
vortex mixing for 1 min. The samples were further 
cleaned using SPE Oasis® HLB cartridges. The clean 
up was done as mentioned in our previous publica-
tion [32] and reconstituted in 200 μl of methanol. A 
volume of 20 μl was injected with the auto sampler 
temperature set at 15°C.
ESNEE clinical study & sample collection
The Ethical approval for the ESNEE study was 
granted by National Research Ethics Service Com-
mittee North West - Greater Manchester North, ref 
no 11/NW/0665. The samples in Estonia were col-
lected under the ethical approval from the University 
of Tartu (210/T-11). DBS sampling was used to collect 
opportunistic blood samples (15 μl) from the neonates 
who had been administered parabens containing for-
mulations. A total number of 927 DBS samples were 
collected from 196 neonates from 4 UK and 1 site from 
Estonia. The study was registered with International 
Standard Randomised Controlled Trial (ISRCTN 
31837223).
Method validation
US FDA guidelines [35] were applied for all the 
validation experiments.
Six different sources of the blank DBS samples were 
used to determine the selectivity. To assess linearity, 
five calibration curves were analyzed on five consecu-
tive days. The slopes, intercepts, correlation (r), the 
weighting factor (1/X2) fitted for the calibration curves 
by least-squares linear regression and the LOQ were all 
calculated as previously reported [32]. Accuracy (%RE) 
and precision (%RSD) were calculated by the analyz-
ing five replicate sets on five separate occasion, of each 
of the four concentrations (20, 40, 200 and 800 ng/ml) 
of the QC samples.
The matrix effect (ME) of parabens and IS was 
monitored at three different concentrations (20, 200, 
800 ng/ml) and was calculated by comparing the 
responses from postextracted spiked samples to the 
pure solutions. The ratio <85% or >115% implies an 
exogenous ME, if the ratio equals to 100, it implies the 
absence of ME. Whereas, ME (%) below or above 100 
indicates ion suppression or enhancement, respectively.
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The MS response (pre-extracted to postextracted 
spiked sample) into a blank matrix was compared with, 
to determine recovery. Stability of MPB, PPB and IS in 
stock solution was tested at the storage temperature of 
4°C (for 1, 3 and 6 months) and stability of the stock 
solutions was tested at room temperature for upto 24 h 
at 20°C. This was done by comparing the area response 
with those of freshly prepared stock solution. Stability 
of the spiked DBS samples stored at -20°C was assessed 
over a period of 24 h, 1, 3, 6 months and 1 year. For 
this, freshly spiked DBS samples were extracted and the 
ratio of peak areas (parabens to IS) was compared with 
the stored DBS samples. Since this was the first time any 
study was carried out to analyze these parabens in the 
DBS, it was collectively decided by the clinicians and 
the analysts that the samples (both spiked and patient) 
will be stored at -20°C on the hospital premises as well 
as on the analytical laboratory site, until analysis. These 
samples were very precious, as the number of spots 
available for the analysis from the neonates were limited.
Blood plasma partitioning of parabens
The blood plasma partitioning for both the para-
bens was performed as per the protocol described by 
Yu et al. [36]. Two concentrations were chosen 20 and 
500 ng/ml for the experiment. Both, spiked reference 
plasma and the whole blood plasma were incubated at 
37°C for 1 h and sampling was done at 0, 10, 30 and 
60 min. These samples were then analyzed. The blood 
plasma ratio was calculated using the equation below. 
Hematocrit of the blood was measured as soon as it was 
collected from healthy volunteers.
KRBC/PL =
1
H
×
IREF PL
IPL – 1
+1
where I 
REF PL
 is instrument response for Reference 
plasma and I 
PL
 is instrument response for whole blood 
plasma (equilibrating plasma) and H is the hematocrit.
Results & discussion
Extraction
Extraction of parabens from the DBS samples was 
optimized using different solvents or solvent mix-
tures such as 100% methanol, 100% water, metha-
nol/water (25, 50 and 75%), 100% acetonitrile and 
acetonitrile/water (25, 50 and 75%). Spiked DBS sam-
ples (20, 100 and 800 ng/ml) were extracted in each 
of the solvents/solvent mixtures for a period of 15, 30, 
45, 60, 75, 90 and 105 min. Extracted samples at each 
time point were analyzed. Results showed that metha-
nol was the best solvent and that 30 min was sufficient 
to extract the parabens present in the samples.
BPB is structurally and chemically similar to MPB 
and PPB, hence was used as an IS. No stable-isotope 
labeled IS was used. SPE was used as a sample clean-
up step, to reduce the ME and any interference aris-
ing from the endogenous species present in the matrix. 
The SPE clean-up also showed a two-fold increase in 
sensitivity of MPB and PPB.
Metabolites, chromatography & selectivity
The chromatography showed no interference or ME 
in both (spiked and patient samples) at the retention 
times of IS and parabens. The main metabolite of 
the parabens is p-hydroxy benzoic acid (m/z 138.12). 
No interference from this metabolite was seen at the 
multiple reaction monitorings of MPB, PPB and BPB 
(IS), as the molecular ions were set for m/z 150.90, 
178.96 and 227.00, respectively, for quadrupole 1. 
Some patient samples showed a peak Figure 2, which 
eluted approximately 1 min before both the parabens. 
Some drug metabolites or ISs can undergo fragmenta-
tion in the source of the mass spectrometer. These sub-
stances should be well-separated chromatographically 
from the parent drug before they reach the ion source 
for proper quantification. The peak seen in Figure 2 
was well separated and was identified as a glucuro-
nide metabolite of the two parabens. Glucuronidation 
is a common biotransformation mechanism in drug 
metabolism. It is a well-known phenomenon, that 
glucuronides undergo in-source dissociation in both 
positive and negative electrospray ionization. This 
is mainly induced by cone voltage, due to which the 
resulting product ions have the same m/z values of 
precursor ions of the parent analyte [37,38]. Chromato-
graphically if the glucuronide and its parent are not 
separated, this would interfere with the quantitation, 
but in our case both of them were well separated and 
did not hinder the quantitation.
The aim of this observational study was to look 
at the circulating concentrations of the parent para-
bens (MPB and PPB) in the neonatal blood samples 
and hence no attempt was made to quantify these 
metabolites.
Linearity, limit of quantification, imprecision 
& recovery
The LOQ for both the parabens was calculated at 
20 ng/ml. Calibration plots of both the parabens in 
DBS samples were constructed using weighted (1/X2) 
linear regression. The% deviation for each calibration 
points was less than 10%. Quanlynx software was 
used to perform the quantification of the parabens. 
The calibration curves for both the parabens were lin-
ear over the range 0–1000 ng/ml and a mean r2 = 0.995 
± 0.003 (n = 5). For MPB the mean slope was 0.001 
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Figure 2. Chromatogram of a preterm neonate.
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and intercept was 0.002, similarly for PPB it was 0.014 
and 0.003, respectively.
There was no carryover seen during the analysis, the 
calibration curve and the QC’s passed the FDA valida-
tion criteria [35]. The number of spots available per neo-
nate were 1 or 2 (3, 4 in rare cases), hence the incurred 
sample reanalysis could not be performed. Based on 
our pilot study, the clinical data and dosage informa-
tion, we had an estimation of range of concentrations 
in the samples, which fell within the calibration curve, 
hence the dilution test was not performed.
The validation data (inter- and intra-day) for 
MPB are shown in Table 1 and PPB in Table 2. The 
data obtained were within the FDA guidelines [35]. 
Inter- and intra-day variations for both the parabens 
were established by the analysis of five replicate sets 
of each of the four concentrations (20, 40, 200 and 
800 ng/ml) of the QC samples on five separate occa-
sions. The interday imprecision was between 1.1 
and 3.4% for MPB and 1.1 and 4.3% for PPB. The 
intraday imprecision was between 0.05 and 0.1% for 
MPB and 0.02 and 0.14% for PPB. The accuracy 
for both the parabens was well within ±15%. The 
recovery of both the parabens and IS from DBS was 
approximately 75%.
Matrix effect
The reproducibility and accuracy of the assay may get 
affected due to coeluting, endogenous compounds 
from the matrix, which will indirectly affect the out-
come of the kinetic data, hence the FDA have hence 
indicated in their guidelines [35] to assess ME. The 
estimated matrix effect (% ME) on both the parabens 
and IS was found to be within 85% and 115% [39]. 
Table 3 shows% ME on the parabens and the IS, and 
clearly indicates that there is no major ion suppression 
or enhancement on these analytes. The SPE sample 
clean-up method did help to minimize this effect.
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Stability
Stock solution
The stock solution of parabens was stable for 
6 months in methanol at 4°C and for 24 h at room 
temperature.
DBS samples
Spiked DBS stored at −20°C for the period of 24 h, 1, 
3, 6 months and 1 year showed values comparable with 
freshly prepared samples.
Blood plasma partitioning of parabens
For both methyl and propyl parabens, the blood to 
plasma partitioning ratio (K
RBC/PL
) was calculated to be 
1.0 based on the formula mentioned in methods sec-
tion. Therefore, both the parabens distributed equally 
in RBC and plasma. Hence, both whole blood (in our 
case DBS samples) and plasma (not applicable in our 
study) could have been used for sampling.
Sample collection from the patients, 
hematocrit & application of the analytical 
method to the ESNEE clinical study
The blood taken from the neonates was mostly from 
heel pricks which was accurately measured using a 
fixed volume 15 ml capillary device and transferred to 
the cards. Only two to three spots were available (in 
some instances only one spot was taken). To deal with 
the issue of the hematocrit, an 8 mm disk was punched 
from the card, wherein the whole spot was captured 
for analysis. This was based on Fan et al.’s findings [40] 
which discuss how to deal with the hematocrit issue 
especially with the variation expected in neonatal 
patient groups. Whole spot methods eliminate the 
variation from spreading and nonhomogeneity and 
allow for more consistent DBS concentrations, even at 
different hematocrit levels as long as the volume of the 
spotting is accurate. Zheng et al. [41] have also dem-
onstrated that the whole spot approach was effective 
in eliminating the hematocrit effect for the analysis 
of apixaban in human DBS when an accurate blood 
sample volume was collected on DBS cards.
The validated method was applied to the analysis of 
the above clinical samples. A total of 927 DBS sam-
ples from 196 recruited patients (neonates) were ana-
lyzed. Parent(s) or guardian(s) of all eligible patients 
gave informed verbal and written consent. Opportu-
nistic sampling was used to collect samples from each 
patient, wherein a tiny amount of sample was taken 
while the bloods were done for routine laboratory anal-
ysis. Figure 2 represents a chromatogram of a preterm 
neonate, 21 days old, 1.5 kg in weight at a sampling 
time of 16 h postdose of a pediatric formulation con-
taining parabens. The concentrations obtained from 
the patient sample analysis from each hospital site are 
shown in the Figure 3. The hospitals who participated 
in this study were Chester, Leighton (LTGN), LWH 
(Liverpool Women’s Hospital) and Arrowe Park from 
UK and University of Tartu hospital from Estonia. 
Only 40% of MPB and 14% PPB samples yielded 
the concentrations above the LOQ (20 ng/ml). This 
primarily reflects the low amounts of MPB and PPB 
excipients present in pharmaceutical formulations, 
typically 0.1–0.2% w/v and 0.02% w/v, respectively. It 
could also reflect rapid metabolism of the parabens [42] 
in both the gastrointestinal tract and liver.
Conclusion
The aim of the ESNEE was to develop excipient 
kinetic EK models for selected excipients in neonates. 
Relatively very few of the medicines administered to 
neonates are tested in this age group. There is little pre-
vious work on the exposure and safety of the excipients 
within the neonatal population. Hence, to study the 
Table 1. Precision and accuracy data for methyl paraben.
Concentration 
(ng/ml) 
Precision Accuracy
Mean ± SD % RSD (CV)  
Interday 
20 (LOQ) 19.4 ± 0.5 2.5 97.2
40 (LQC) 40.1 ± 1.1 2.7 100.3
200 (MQC) 196.6 ± 6.6 3.4 98.3
800 (UQC) 790.7 ± 8.7 1.1 98.8
Intraday 
20 (LOQ) 18.3 ± 1.5 0.08 91.5
40 (LQC) 42.4 ± 4.2 0.1 106.1
200 (MQC) 206.0 ± 17.8 0.09 103.0
800 (UQC) 768.6 ± 15.8 0.05 96.0
Table 2. Precision and accuracy data for propyl paraben.
Concentration 
(ng/ml) 
Precision Accuracy 
Mean ± SD % RSD (CV)
Interday 
20 (LOQ) 19.7 ± 0.9 4.3 98.4
40 (LQC) 39.6 ± 0.4 1.1 99.1
200 (MQC) 196.0 ± 4.9 2.5 98.0
800 (UQC) 823.0 ± 18.9 2.3 102.9
Intraday 
20 (LOQ) 18.0 ± 2.7 0.14 94.6
40 (LQC) 40.8 ± 2.8 0.07 101.9
200 (MQC) 197.8 ± 18.4 0.09 98.9
800 (UQC) 824.8 ± 21.1 0.02 103.1
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Figure 3. Concentrations obtained from the patient sample analysis from each hospital site. (A) Concentrations 
above LOQ (20 ng/ml); (B) concentrations between 10 and 19 ng/ml. (C) Concentrations below limit of detection 
(10 ng/ml).
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EK, we needed to measure the concentration of each 
excipient in the bloodstream of the neonates. We chose 
a few excipients which are commonly used in these for-
mulations (mainly parabens and ethanol). These were 
then analyzed in different laboratories within our con-
sortium. Our laboratory was involved in developing 
and analyzing parabens from the DBS. This analytical 
data were then used to model EK for parabens which 
has been reported elsewhere [43].
Herein we report a simple, quantitative LC–MS/MS 
DBS parabens assay, which has been successfully devel-
oped, validated and applied to analyze neonatal sam-
ples. The circulating blood concentrations of parabens 
in neonates confirm systemic exposure to these com-
pounds following administration of routine medicines. 
We report the first clinical study of systemic PB expo-
sure in neonates. Only 40% of MPB and 14% PPB 
samples yielded the concentrations above the LOQ 
(20 ng/ml). This analytical data have now been sub-
jected to population EK modeling. The clinical study 
of parabens among the children who received parabens 
in routinely administered medicines showed that the 
circulating concentrations of MPB are not sufficient 
to sustain concerns about long-term outcomes. PPB 
was below the limit of detection in half the children 
studied. This provides reassurance to clinicians, since 
the circulating concentrations are low and any metab-
olites are unlikely to have any endocrine disrupting 
effects [44].
Future perspective
DBS sampling and analysis has evolved fast in the last 
decade. With the increase of sensitivity of the new 
mass spectrometers, the DBS technology will be widely 
accepted by the academics and the industry as a very 
important sampling method. Those involved in animal 
research could reduce the number of animals used to a 
minimum, to obtain information from fewer animals or 
more information from the same number of animals by 
using the DBS technology. In our own work in the field 
Table 3. Matrix effect.
Concentrations (ng/ml)
 
Matrix effect (%)
MPB PPB IS (5 ng/ml)
20 (LOQ) 98.4 96.9 94.6
200 (MQC) 103.4 97.5  
800 (UQC) 100.3 98.2  
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of pediatric research, this technology has been and will 
be very useful in future. To the specifics of our research 
in excipients – more excipients (commonly used in 
pediatric formulations) should be studied for their safe 
use. This could be done using existing expertise within 
Europe with the co-ordination with EMA and the 
pharmaceutical companies, by doing a multicenter trial.
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Executive summary
•	 Measurement of methyl and propyl parabens concentrations from DBS by LC–MS/MS.
•	 DBS sampling was used to collect opportunistic blood samples (15 μl) from the neonates who have been 
administered parabens containing formulations.
•	 One hundred and ninty-six neonates were recruited from four UK and one Estonian site; a total of 927 DBS 
samples were available for analysis.
•	 This study addresses the systemic exposure of parabens to the neonatal population.
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